ARCA BIOPHARMA, INC. SECOND AMENDMENT TO RETENTION BONUS LETTER
Exhibit 10.1
SECOND AMENDMENT TO RETENTION BONUS LETTER
This second amendment (this “Amendment”) is entered into effective as of April 22, 2024 by and between Xxxxxx X. Xxxxx (“Executive”) and ARCA biopharma, Inc. (the “Company,” and together with Executive, the “Parties”).
WHEREAS, the Parties entered into a retention bonus letter agreement dated December 8, 2022 and an amendment to retention bonus letter dated on or about December 4, 2023 (collectively, the “Retention Agreement”).
WHEREAS, the Parties desire to amend the Retention Agreement to increase the aggregate amount of the cash retention bonus by 33.33%.
NOW, THEREFORE, in considerations of the promises, mutual covenants, and above recitals, and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, Executive and the Company hereby agree as follows:
“In recognition of your continued service with ARCA biopharma, Inc. (the “Company”), we are pleased to offer you the opportunity to receive a cash retention bonus in the aggregate amount of $200,000, less applicable withholdings and deductions required by law (the “Retention Bonus”). Subject to the terms of this letter, you will become eligible to receive a portion of the Retention Bonus in the amount of $35,000 on December 8, 2023 (the date of occurrence of such event, the “Payment Event One Date”), and the remaining portion of the Retention Bonus in the amount of $165,000 upon the earlier to occur of the following: (i) a Corporate Transaction (as defined below), or (ii) the date that the board of directors of the Company (the “Board”) approves certain clinical development decisions (the date of occurrence of such event, the “Payment Event Two Date,” and together with Payment Event One Date, each a “Payment Event Date”). Any payment related to the Retention Bonus will be processed and paid to you by the Company via payroll within thirty (30) business days of the date of occurrence of the applicable Payment Event Date, subject to the terms of this letter.”
IN WITNESS WHEREOF, each of the Parties has executed this Amendment, in the case of the Company by its duly authorized officer, effective as of the date set forth above.
|
EXECUTIVE |
C. Xxxx Xxxxxx |
|
Xxxxxx Xxxxx |
By: |
C. Xxxx Xxxxxx |
|
By: |
Xxxxxx Xxxxx |
Date: |
April 22, 2024 |
|
Date: |
April 22, 2024 |
-2-